Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.59 |
| ▸ | MDM4 | O15151 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382791 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL1000115 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL29398487 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL30645689 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL29503829 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL7420121 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL29367120 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL14996025 | 0.96 | TLR2 (0.64) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL14497949 | 0.96 | TLR2 (0.64) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL30802520 | 0.96 | TLR2 (0.64) | TLR2MDM2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250243540-A1 | PROBE RELATED REAGENTS AND METHODS | BRENTANO BIOTECHNOLOGY ASSOCIATES (US) | 2025-07-31 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-12077555-B2 | STAT degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| WO-2024043341-A1 | CYCLOALKYNE DERIVATIVE | ペプチドリーム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| WO-2001091739-A2 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASTIC DISEASE USING CHEMOTHERAPY AND RADIATION SENSITIZERS | CHIRON CORPORATION (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001013957-A2 | ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES USING OLIGO ARGININE MOIETIES | CELLGATE, INC. (US) | 2001-03-01 | — | — | WO | disclosed |
| US-6031091-A | WITH PROTECTING GROUPS WHICH MAY BE REMOVED FOR COUPLING TO ANOTHER NUCLEOTIDE; FOR HYBRIDIZATION PROBES WITH ENHANCED SENSITIVITY | GEN-PROBE INCORPORATED (US) | 2000-02-29 | — | — | US | disclosed |
| US-5696251-A | OLIGONUCLEOTIDES | GEN-PROBE INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5656744-A | COMPLEXING | GEN-PROBE INCORPORATED (US) | 1997-08-12 | — | — | US | disclosed |
| US-5585481-A | VERSATILITY; NON-NUCLEOTIDE MONOMERIC UNIT HAVING A LIGAND AND FIRST AND SECOND COUPLING GROUPS WHICH ARE LINKED TO THE NON-NUCLEOTIDE MONOMERIC UNIT ; LABELS, INTERCALATORS, PROBES | GEN-PROBE INCORPORATED (US) | 1996-12-17 | — | — | US | disclosed |
| EP-0546055-B1 | POLYETHYLENE GLYCOL DERIVATIVES FOR SOLID-PHASE APPLICATIONS | UNIV MINNESOTA (US) | 1996-07-10 | — | — | EP | disclosed |
| EP-0313219-B1 | Non-nucleotide linking reagents for nucleotide probes | GEN PROBE INC (US) | 1996-05-08 | — | — | EP | disclosed |
| EP-0313219-A2 | Non-nucleotide linking reagents for nucleotide probes | GEN-PROBE INCORPORATED (US) | 1989-04-26 | — | — | EP | disclosed |
| WO-1989002439-A1 | NON-NUCLEOTIDE LINKING REAGENTS FOR NUCLEOTIDE PROBES | ML TECHNOLOGY VENTURES, L.P. (US) | 1989-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077555-B2 | STAT degraders and uses thereof | STAT4, STAT1, STAT3 | TLR2 1185/4885MDM2 17/4885MDM4 156/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | TLR2 3821/4885MDM2 164/4885MDM4 441/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | TLR2 4611/4885MDM2 1604/4885MDM4 1294/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | TLR2 3821/4885MDM2 164/4885MDM4 441/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | TLR2 3196/4885MDM2 85/4885MDM4 1577/4885 |
| US-20250243540-A1 | PROBE RELATED REAGENTS AND METHODS | DNTT, NCL, NT5C3B | TLR2 1774/4885MDM2 351/4885MDM4 151/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | TLR2 4097/4885MDM2 2036/4885MDM4 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.